|
1
|
Agrawal NM, Campbell DR, Safdi MA, Lukasik
NL, Huang B and Haber MM: Superiority of lansoprazole vs ranitidine
in healing nonsteroidal anti-inflammatory drug-associated gastric
ulcers: Results of a double-blind, randomized, multicenter study.
NSAID-associated gastric Ulcer study group. Arch Intern Med.
160:1455–1461. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chiba N, De Gara CJ, Wilkinson JM and Hunt
RH: Speed of healing and symptom relief in grade II to IV
gastresophageal reflux disease: A meta-analysis. Gastroenterology.
112:1798–1810. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dekkers CP, Beker JA, Thjodleifsson B,
Gabryelewicz A, Bell NE and Humphries TJ: Comparison of rabeprazole
20 mg versus omeprazole 20 mg in the treatment of active duodenal
ulcer: A European multicentre study. Aliment Pharmacol Ther.
13:179–186. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Farley A, Wruble LD and Humphries TJ:
Rabeprazole versus ranitidine for the treatment of erosive
gastresophageal reflux disease: A double-blind, randomized clinical
trial. Raberprazole study group. Am J Gastroenterol. 95:1894–1899.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang JQ and Hunt RH: pH, healing rate and
symptom relief in acid-related diseases. Yale J Biol Med.
69:159–174. 1996.PubMed/NCBI
|
|
6
|
Lew EA, Pisegna JR, Starr JA, Soffer EF,
Forsmark C, Modlin IM, Walsh JH, Beg M, Bochenek W and Metz DC:
Intravenous pantoprazole rapidly controls gastric acid
hypersecretion in patients with Zollinger-Ellison syndrome.
Gastroenterology. 118:696–704. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Norton JA, Fraker DL, Alexander HR, Venzon
DJ, Doppman JL, Serrano J, Goebel SU, Peghini PL, Roy PK, Gibril F
and Jensen RT: Surgery to cure the Zollinger-Ellison syndrome. N
Engl J Med. 34:635–644. 1999. View Article : Google Scholar
|
|
8
|
Farrell B, Lass E, Moayyedi P, Ward D and
Thompson W: Reduce unnecessary use of proton pump inhibitors. BMJ.
379:e0692112022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Forgacs I and Loganayagam A:
Overprescribing proton pump inhibitors. BMJ. 336:2–3. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Connelly D: The development and safety of
proton pump inhibitors. The Pharm J. 296:78902016.
|
|
11
|
Lanza FL, Chan FK and Quigley EM:
Guidelines for prevention of NSAID-related ulcer complications. Am
J Gastroenterol. 104:728–738. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Targownik LE, Fisher DA and Saini SD: AGA
clinical practice update on de-prescribing of proton pump
inhibitors: Expert review. Gastroenterol. 162:1334–1342. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Malfertheiner P, Chan FK and McColl KE:
Peptic ulcer disease. Lancet. 374:1449–1461. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jankowski JAZ, de Caestecker J, Love SB,
Reilly G, Watson P, Sanders S, Ang Y, Morris D, Bhandari P, Brooks
C, et al: Esomeprazole and aspirin in Barrett's esophagus (AspECT):
A randomised factorial trial. Lancet. 392:400–408. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Othman F, Card TR and Crooks CJ: Proton
pump inhibitor prescribing patterns in the UK: A primary care
database study. Pharmacoepidemiol Drug Saf. 25:1079–1087. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Blackett JW, Faye AS, Phipps M, Li J,
Lebwohl B and Freedberg DE: Prevalence and risk factors for
inappropriate continuation of proton pump inhibitors after
discharge from the intensive care unit. Mayo Clin Proc.
96:2550–2560. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nguyen PV and Tamaz R: Inappropriate
prescription of proton pump inhibitors in a community setting. Can
J Hosp Pharm. 71:267–271. 2018.PubMed/NCBI
|
|
18
|
Cao F, Chen CX, Wang M, Liao HR, Wang MX,
Hua SZ, Huang B, Xiong Y, Zhang JY and Xu YL: Updated meta-analysis
of controlled observational studies: Proton-pump inhibitors and
risk of Clostridium difficile infection. J Hosp Infect. 98:4–13.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang CH, Li CH, Hsieh R, Fan CY, Hsu TC,
Chang WC, Hsu WT, Lin YY and Lee CC: Proton pump inhibitors therapy
and the risk of pneumonia: A systematic review and meta-analysis of
randomized controlled trials and observational studies. Expert Opin
Drug Saf. 18:163–172. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li M, Luo Z, Yu S and Tang Z: Proton pump
inhibitor use and risk of dementia: Systematic review and
meta-analysis. Medicine (Baltimore). 98:e144222019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu J, Li X, Fan L, Yang J, Wang J, Sun J
and Wang Z: Proton pump inhibitors therapy and risk of bone
diseases: An update meta-analysis. Life Sci. 218:213–223. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang ML, Fan YX, Meng R, Cai WK, Yin SJ,
Zhou T, Huang YH, Wang P, Jiang FF, Yang M and He GH: Proton pump
inhibitors and cancer risk: An umbrella review and meta-analysis of
observational studies. Am J Clin Oncol. 45:475–485. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Verdu E, Viani F, Armstrong D, Fraser R,
Siegrist HH, Pignatelli B, Idström JP, Cederberg C, Blum AL and
Fried M: Effect of omeprazole on intragastric bacterial counts,
nitrates, nitrites, and N-nitroso compounds. Gut. 35:455–460. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Imhann F, Bonder MJ, Vila AV, Fu J,
Mujagic Z, Vork L, Tigchelaar EF, Jankipersadsing SA, Cenit MC,
Harmsen HJ, et al: Proton pump inhibitors affect the gut
microbiome. Gut. 65:740–748. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lundell L, Vieth M, Gibson F, Nagy P and
Kahrilas PJ: Systematic review: The effects of long-term proton
pump inhibitor use on serum gastrin levels and gastric histology.
Aliment Pharmacol Ther. 42:649–663. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Feng J, Petersen CD, Coy DH, Jiang JK,
Thomas CJ, Pollak MR and Wank SA: Calcium-sensing receptor is a
physiologic multimodal chemosensor regulating gastric G-cell growth
and gastrin secretion. Proc Natl Acad Sci USA. 107:17791–17796.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nguyen DM, El-Serag HB, Henderson L, Stein
D, Bhattacharyya A and Sampliner RE: Medication usage and the risk
of neoplasia in patients with Barrett's esophagus. Clin
Gastroenterol Hepatol. 7:1299–1304. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Poulsen AH, Christensen S, McLaughlin JK,
Thomsen RW, Sørensen HT, Olsen JH and Friis S: Proton pump
inhibitors and risk of gastric cancer: A population-based cohort
study. Br J Cancer. 100:1503–1507. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Boursi B, Finkelman B, Giantonio BJ,
Haynes K, Rustgi AK, Rhim AD, Mamtani R and Yang YX: A clinical
prediction model to assess risk for pancreatic cancer among
patients with new-onset diabetes. Gastroenterology. 152:840–850.e3.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brusselaers N, Wahlin K, Engstrand L and
Lagergren J: Maintenance therapy with proton pump inhibitors and
risk of gastric cancer: A nationwide population-based cohort study
in Sweden. BMJ Open. 7:e0177392017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hwang IC, Chang J and Park SM: Emerging
hazard effects of proton pump inhibitor on the risk of colorectal
cancer in low-risk populations: A Korean nationwide prospective
cohort study. PLoS One. 12:e01891142017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wennerström ECM, Simonsen J, Camargo MC
and Rabkin CS: Acid-suppressing therapies and subsite-specific risk
of stomach cancer. Br J Cancer. 116:1234–1238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheung KS, Chan EW, Wong AYS, Chen L, Wong
ICK and Leung WK: Long-term proton pump inhibitors and risk of
gastric cancer development after treatment for Helicobacter pylori:
A population-based study. Gut. 67:28–35. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hwang IC, Chang J and Park SM: Association
between proton pump inhibitor use and the risk of pancreatic
cancer: A Korean nationwide cohort study. PLoS One.
13:e02039182018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li DK, Yan P, Abou-Samra AB, Chung RT and
Butt AA: Proton pump inhibitors are associated with accelerated
development of cirrhosis, hepatic decompensation and hepatocellular
carcinoma in noncirrhotic patients with chronic hepatitis C
infection: Results from ERCHIVES. Aliment Pharmacol Ther.
47:246–258. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tran KT, McMenamin ÚC, Hicks B, Murchie P,
Thrift AP, Coleman HG, Iversen L, Johnston BT, Lee AJ and Cardwell
CR: Proton pump inhibitor and histamine-2 receptor antagonist use
and risk of liver cancer in two population-based studies. Aliment
Pharmacol Ther. 48:55–64. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brusselaers N, Lagergren J and Engstrand
L: Duration of use of proton pump inhibitors and the risk of
gastric and esophageal cancer. Cancer Epidemiol. 62:1015852019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kao WY, Su CW, Chia-Hui Tan E, Lee PC,
Chen PH, Tang JH, Huang YH, Huo TI, Chang CC, Hou MC, et al: Proton
pump inhibitors and risk of hepatocellular carcinoma in patients
with chronic hepatitis B or C. Hepatology. 69:1151–1164. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Babic A, Zhang X, Morales-Oyarvide V, Yuan
C, Khalaf N, Khalili H, Lochhead P, Chan AT, Ogino S, Wolpin BM, et
al: Acid-suppressive medications and risk of colorectal cancer:
Results from three large prospective cohort studies. Br J Cancer.
123:844–851. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Brusselaers N, Sadr-Azodi O and Engstrand
L: Long-term proton pump inhibitor usage and the association with
pancreatic cancer in Sweden. J Gastroenterol. 55:453–461. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu P, McMenamin ÚC, Johnston BT, Murchie
P, Iversen L, Lee AJ, Vissers PAJ and Cardwell CR: Use of proton
pump inhibitors and histamine-2 receptor antagonists and risk of
gastric cancer in two population-based studies. Br J Cancer.
123:307–315. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kamal H, Sadr-Azodi O, Engstrand L and
Brusselaers N: Association between proton pump inhibitor use and
biliary tract cancer risk: A Swedish population-based cohort study.
Hepatology. 74:2021–2031. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lei WY, Wang JH, Yi CH, Liu TT, Hung JS,
Wong MW, Bair MJ, Vaezi MF, Orr WC and Chen CL: Association between
use of proton pump inhibitors and colorectal cancer: A nationwide
population-based study. Clin Res Hepatol Gastroenterol.
45:1013972021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ng AK, Ng PY, Ip A, Cheung KS and Siu CW:
Association between proton pump inhibitors after percutaneous
coronary intervention and risk of gastric cancer. BMJ Open
Gastroenterol. 8:e0007192021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Seo SI, Park CH, You SC, Kim JY, Lee KJ,
Kim J, Kim Y, Yoo JJ, Seo WW, Lee HS and Shin WG: Association
between proton pump inhibitor use and gastric cancer: A
population-based cohort study using two different types of
nationwide databases in Korea. Gut. 70:2066–2075. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shin GY, Park JM, Hong J, Cho YK, Yim HW
and Choi MG: Use of proton pump inhibitors vs histamine 2 receptor
antagonists for the risk of gastric cancer: Population-based cohort
study. Am J Gastroenterol. 116:1211–1219. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Abrahami D, McDonald EG, Schnitzer ME,
Barkun AN, Suissa S and Azoulay L: Proton pump inhibitors and risk
of gastric cancer: population-based cohort study. Gut. 71:16–24.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Abrahami D, McDonald EG, Schnitzer ME,
Barkun AN, Suissa S and Azoulay L: Proton pump inhibitors and risk
of colorectal cancer. Gut. 71:111–118. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gong EJ, Bang CS, Kim DK, Lee JJ and Baik
GH: Use of proton pump inhibitors and the risk for the development
of gastric cancers: A nationwide population-based cohort study
using balanced operational definitions. Cancers. 14:51722022.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Segna D, Brusselaers N, Glaus D, Krupka N
and Misselwitz B: Association between proton-pump inhibitors and
the risk of gastric cancer: A systematic review with meta-analysis.
Therap Adv Gastroenterol. 14:175628482110514632021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tran-Duy A, Spaetgens B, Hoes AW, de Wit
NJ and Stehouwer CD: Use of proton pump inhibitors and risks of
fundic gland polyps and gastric cancer: Systematic review and
meta-analysis. Clin Gastroenterol Hepatol. 14:1706–1719.e5. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ma T, Wu M, Jia S and Yang L: Proton pump
inhibitors and the risk of colorectal cancer: A systematic review
and meta-analysis of observational studies. Int J Colorectal Dis.
35:2157–2169. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Laoveeravat P, Thavaraputta S,
Vutthikraivit W, Suchartlikitwong S, Mingbunjerdsuk T, Motes A,
Nugent K, Rakvit A, Islam E and Islam S: Proton pump inhibitors and
histamine-2 receptor antagonists on the risk of pancreatic cancer:
A systematic review and meta-analysis. QJM. 113:100–107.
2020.PubMed/NCBI
|
|
54
|
Alkhushaym N, Almutairi AR, Althagafi A,
Fallatah SB, Oh M, Martin JR, Babiker HM, McBride A and Abraham I:
Exposure to proton pump inhibitors and risk of pancreatic cancer: A
meta-analysis. Expert Opin Drug Saf. 19:327–334. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: The PRISMA 2020 statement: An updated guideline for
reporting systematic reviews. BMJ. 372:n712021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wells GA, Shea B, O'Connell D, et al: The
newcastle-ottawa scale (NOS) for assessing the quality of
nonrandomised studies in meta-analyses. Ottawa Hospital Research
Institute. Ottawa; ON, Canada: 2000
|
|
57
|
Higgins JP and Thompson SG: Quantifying
heterogeneity in a meta-analysis. Stat Med. 21:1539–1558. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
DerSimonian R and Kacker R: Random-effects
model for meta-analysis of clinical trials: An update. Contemp Clin
Trials. 28:105–114. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Macaskill P, Walter SD and Irwig L: A
comparison of methods to detect publication bias in meta-analysis.
Stat Med. 20:641–654. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lee Y, Urbanska AM, Hayakawa Y, Wang H, Au
AS, Luna AM, Chang W, Jin G, Bhagat G, Abrams JA, et al: Gastrin
stimulates a cholecystokinin-2-receptor-expressing cardia
progenitor cell and promotes progression of Barrett's-like
esophagus. Oncotarget. 8:203–214. 2016. View Article : Google Scholar
|
|
61
|
Betton GR, Dormer CS, Wells T, Pert P,
Price CA and Buckley P: Gastric ECL-cell hyperplasia and carcinoids
in rodents following chronic administration of H2-antagonists
SK&F 93479 and oxmetidine and omeprazole. Toxicol Pathol.
16:288–298. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kidd M, Tang LH, Modlin IM, Zhang T, Chin
K, Holt PR and Moss SF: Gastrin-mediated alterations in gastric
epithelial apoptosis and proliferation in a mastomys rodent model
of gastric neoplasia. Digestion. 62:143–151. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Joo MK, Park JJ and Chun HJ: Proton pump
inhibitor: The dual role in gastric cancer. World J Gastroenterol.
25:2058–2070. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Henwood M, Clarke P, Smith AM and Watson
SA: Expression of gastrin in developing gastric adenocarcinoma. Br
J Surg. 88:564–568. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wroblewski LE, Peek RM and Coburn LA: The
role of the microbiome in gastrointestinal cancer. Gastroenterol
Clin North Am. 45:543–556. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Weitsman S, Celly S, Leite G, Mathur R,
Sedighi R, Barlow GM, Morales W, Sanchez M, Parodi G,
Villanueva-Millan MJ, et al: Effects of proton pump inhibitors on
the small bowel and stool microbiomes. Dig Dis Sci. 67:224–232.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Waldum HL, Sørdal Ø and Fossmark R: Proton
pump inhibitors (PPIs) may cause gastric cancer-clinical
consequences. Scand J Gastroenterol. 53:639–642. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zeng X, Liu L, Zheng M, Sun H, Xiao J, Lu
T, Huang G, Chen P, Zhang J, Zhu F, et al: Pantoprazole, an
FDA-approved proton-pump inhibitor, suppresses colorectal cancer
growth by targeting T-cell-originated protein kinase. Oncotarget.
7:22460–22473. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Patlolla JM, Zhang Y, Li Q, Steele VE and
Rao CV: Anti-carcinogenic properties of omeprazole against human
colon cancer cells and azoxymethane-induced colonic aberrant crypt
foci formation in rats. Int J Oncol. 40:170–175. 2012.PubMed/NCBI
|
|
70
|
Watson SA and Smith AM: Hypergastrinemia
promotes adenoma progression in the APC(Min-/+) mouse model of
familial adenomatous polyposis. Cancer Res. 61:625–631.
2001.PubMed/NCBI
|
|
71
|
Jiang K, Jiang X, Wen Y, Liao L and Liu
FB: Relationship between long-term use of proton pump inhibitors
and risk of gastric cancer: A systematic analysis. J Gastroenterol
Hepatol. 34:1898–1905. 2019. View Article : Google Scholar : PubMed/NCBI
|
